Table 4 Comparison of Clinicopathologic Variables between the Analysis Cohort and the External Validation Cohort.

From: Multi-institutional development and validation of a novel histologic grading system for colonic graft-versus-host disease

 

Analysis Cohort (N = 191)

External Validation Cohort (N = 97)

P-valuea

Total (N = 288)

Male sex

101 (52.9%)

55 (56.7%)

0.54

156 (54.2%)

Age at biopsy, years

  Median (Range)

58.0 (20.0–75.0)

50.7 (1.4, 72.2)

<0.0001

57.0 (1.4, 75.0)

Apoptotic count per 10 contiguous crypts

  Median (Range)

6 (0–76)

18 (1–51)

<0.0001

10 (0–76)

  Q1, Q3

2, 17

10, 26

 

3, 22

Apoptotic score

  No apoptosis [0]

22 (11.5%)

0 (0.0%)

<0.0001

22 (7.6%)

  1–6 apoptotic bodies [1]

77 (40.3%)

11 (11.3%)

 

88 (30.6%)

  >6 apoptotic bodies [2]

92 (48.2%)

86 (88.7%)

 

178 (61.8%)

Crypt score

  No crypt dropout [0]

112 (58.6%)

42 (43.3%)

0.02

154 (53.5%)

  Crypt dropout [1]

47 (24.6%)

27 (27.8%)

 

74 (25.7%)

  Ulceration [2]

32 (16.8%)

28 (28.9%)

 

60 (20.8%)

Novel grade (apoptotic + crypt score) – original apoptotic scoring

  0

21 (11.0%)

0 (0.0%)

<0.0001

21 (7.3%)

  1

65 (34.0%)

10 (10.3%)

 

75 (26.0%)

  2

36 (18.8%)

32 (33.0%)

 

68 (23.6%)

  3

41 (21.5%)

28 (28.9%)

 

69 (24.0%)

  4

28 (14.7%)

27 (27.8%)

 

55 (19.1%)

Endoscopy findings

  Normal

77 (46.4%)

64 (66.7%)

0.0003

141 (53.8%)

  Subtle

47 (28.3%)

23 (24.0%)

 

70 (26.7%)

  Exudate

8 (4.8%)

5 (5.2%)

 

13 (5.0%)

  Ulcer

34 (20.5%)

4 (4.2%)

 

38 (14.5%)

Lerner grade

  0

21 (11.0%)

0 (0.0%)

<0.0001

21 (7.3%)

  1

91 (47.6%)

27 (27.8%)

 

118 (41.0%)

  2

21 (11.0%)

14 (14.4%)

 

35 (12.2%)

  3

26 (13.6%)

28 (28.9%)

 

54 (18.8%)

  4

32 (16.8%)

28 (28.9%)

 

60 (20.8%)

Other organ GVHD

  No

98 (51.3%)

60 (61.9%)

0.09

158 (54.9%)

  Yes

93 (48.7%)

37 (38.1%)

 

130 (45.1%)

Treatment for GVHD

  No

42 (22.0%)

1 (1.0%)

<0.0001

43 (14.9%)

  Yes

149 (78.0%)

96 (99.0%)

 

245 (85.1%)

Days from transplant to biopsy

  Median (Range)

61 (14–3650)

69 (15–709)

0.46

65 (13–3650)

  Q1, Q3

28, 182

32, 122

 

30, 168

Total follow-up years since biopsyb

  Median (Range)

1.4 (0–9.8)

0.4 (0–8.9)

0.001

1.1 (0–9.8)

  Q1, Q3

0.4, 3.2

0.1, 3.0

 

0.2, 3.2

Status at last follow up, N

  Alive

95

30

 

125

  Deceased

96

67

 

163

GVHD-related death within 6 months

26 (13.6%)

19 (19.6%)

0.19

45 (15.6%)

  1. aP-values comparing distributions using chi-square tests for nominal characteristics; Wilcoxon rank-sum for ordinal and continuous characteristics.
  2. bAll patients who were not deceased within 6 months have at least 6 months of follow-up available. The external validation cohort is more recent (less follow-up time available).
Back to article page